← Back to Screener
PERRIGO COMPANY PLC (PRGO)
Price$11.42
Favorite Metrics
Price vs S&P 500 (26W)-51.28%
Price vs S&P 500 (4W)8.97%
Market Capitalization$1.58B
Indicated Dividend Yield (Annual)10.17%
All Metrics
P/CF (Annual)6.64x
Book Value / Share (Quarterly)$21.33
P/TBV (Annual)3.31x
Indicated Dividend (Annual)$1.16
Revenue Growth (3Y)-1.51%
Cash Flow / Share (Quarterly)$1.05
Payout Ratio (TTM)532.00%
Price vs S&P 500 (YTD)-20.67%
Gross Margin (TTM)35.14%
Net Profit Margin (TTM)-33.51%
EPS (TTM)$-10.36
10-Day Avg Trading Volume3.47M
EPS Excl Extra (TTM)$-10.36
Revenue Growth (5Y)0.79%
EPS (Annual)$-10.29
Dividend / Share (Annual)$1.16
ROI (Annual)-21.68%
Gross Margin (Annual)35.14%
Net Profit Margin (5Y Avg)-8.51%
Cash / Share (Quarterly)$3.86
Revenue Growth QoQ (YoY)-2.52%
ROA (Last FY)-16.70%
Revenue Growth TTM (YoY)-2.75%
EBITD / Share (TTM)$-5.77
ROE (5Y Avg)-11.41%
Operating Margin (TTM)-26.39%
Cash Flow / Share (Annual)$1.05
P/B Ratio0.54x
P/B Ratio (Quarterly)0.65x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.10x
Net Interest Coverage (TTM)-6.98x
ROA (TTM)-14.82%
EV / EBITDA (TTM)7.84x
EPS Incl Extra (Annual)$-10.29
Current Ratio (Annual)2.76x
Quick Ratio (Quarterly)1.44x
3-Month Avg Trading Volume3.47M
52-Week Price Return-54.36%
EV / Free Cash Flow (Annual)32.33x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$4.21
P/S Ratio (Annual)0.37x
Asset Turnover (Annual)0.50x
52-Week High$28.43
Operating Margin (5Y Avg)-1.99%
EPS Excl Extra (Annual)$-10.29
CapEx CAGR (5Y)-14.60%
Tangible BV CAGR (5Y)-26.39%
26-Week Price Return-47.30%
Quick Ratio (Annual)1.44x
13-Week Price Return-23.63%
Total Debt / Equity (Annual)1.24x
Current Ratio (Quarterly)2.76x
Enterprise Value$4,691.568
Revenue / Share Growth (5Y)0.44%
Asset Turnover (TTM)0.44x
Book Value / Share Growth (5Y)-12.88%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.47x
Pretax Margin (Annual)-30.52%
Cash / Share (Annual)$3.86
3-Month Return Std Dev49.38%
Gross Margin (5Y Avg)34.68%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)-8.13%
EBITDA Interim CAGR (5Y)-3.50%
ROE (Last FY)-48.56%
Net Interest Coverage (Annual)-6.94x
EPS Basic Excl Extra (Annual)$-10.29
P/FCF (TTM)6.73x
Receivables Turnover (TTM)6.37x
EV / Free Cash Flow (TTM)32.33x
Total Debt / Equity (Quarterly)1.24x
EPS Incl Extra (TTM)$-10.36
Receivables Turnover (Annual)6.37x
ROI (TTM)-18.52%
Dividend Growth Rate (5Y)4.76%
P/S Ratio (TTM)0.37x
Pretax Margin (5Y Avg)-5.88%
Revenue / Share (Annual)$30.71
Tangible BV / Share (Annual)$4.21
Forward P/E5.39x
Free OCF CAGR (5Y)-19.55%
Price vs S&P 500 (52W)-84.19%
Year-to-Date Return-18.03%
5-Day Price Return7.64%
EPS Normalized (Annual)$-10.29
ROA (5Y Avg)-4.11%
Net Profit Margin (Annual)-33.51%
Month-to-Date Return6.24%
Cash Flow / Share (TTM)$2.81
EBITD / Share (Annual)$-5.76
Operating Margin (Annual)-27.18%
LT Debt / Equity (Annual)1.22x
P/CF (TTM)6.64x
ROI (5Y Avg)-5.27%
LT Debt / Equity (Quarterly)1.22x
EPS Basic Excl Extra (TTM)$-10.36
P/TBV (Quarterly)3.31x
P/B Ratio (Annual)0.65x
Dividend / Share (TTM)$1.16
Inventory Turnover (TTM)2.47x
Pretax Margin (TTM)-30.51%
Book Value / Share (Annual)$21.33
Price vs S&P 500 (13W)-24.32%
Dividend Yield (TTM)10.06%
Beta0.50x
P/FCF (Annual)10.91x
Revenue / Share (TTM)$30.91
ROE (TTM)-35.16%
52-Week Low$9.22
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.80
3.80
3.80
3.80
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PRGOPERRIGO COMPANY PLC | 0.37x | -2.75% | 35.14% | — | $11.42 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Perrigo is a global consumer health company specializing in self-care products. Its North American business, representing approximately two-thirds of sales, operates as a major private-label supplier to retailers including Walmart, Amazon, Costco, and CVS. Internationally, it markets branded products—including Compeed, Solpadeine, Coldrex, and ellaOne—in Europe, Australia, and select Asian markets. The dual strategy balances high-volume private-label revenue with branded product margins.